Chan Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2289294/publications.pdf Version: 2024-02-01



Сная Кім

#	Article	IF	CITATIONS
1	Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. Current Problems in Cancer, 2022, 46, 100848.	2.0	5
2	The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211132.	3.2	10
3	Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. Gene Therapy, 2021, 28, 186-198.	4.5	16
4	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2021, 74, 350-359.	3.7	122
5	STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. , 2021, 9, e002195.		49
6	Abstract 1914: Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer. , 2021, , .		3
7	Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2021, 22, 9414.	4.1	46
8	Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer. Cancers, 2021, 13, 4906.	3.7	18
9	Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. Oncolmmunology, 2021, 10, 2005280.	4.6	6
10	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. , 2021, 9, e003353.		14
11	Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway. Frontiers in Oncology, 2021, 11, 768022.	2.8	0
12	Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. International Journal of Molecular Sciences, 2020, 21, 7743.	4.1	36
13	Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. , 2020, 8, e000857.		37
14	Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. Cancers, 2020, 12, 3123.	3.7	33
15	Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Experimental and Molecular Medicine, 2020, 52, 1475-1485.	7.7	306
16	Targeting Actomyosin Contractility Suppresses Malignant Phenotypes of Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences, 2020, 21, 3460.	4.1	5
17	REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. Chinese Clinical Oncology, 2020, 9, 58-58.	1.2	1
18	Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Clinical Cancer Research, 2019, 25, 1612-1623.	7.0	120

Снал Кім

#	Article	IF	CITATIONS
19	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. Gastric Cancer, 2019, 22, 113-122.	5.3	16
20	STING signaling is a potential immunotherapeutic target in colorectal cancer. Journal of Cancer, 2019, 10, 4932-4938.	2.5	51
21	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. European Journal of Cancer, 2019, 112, 20-28.	2.8	2
22	STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. Journal of Clinical Investigation, 2019, 129, 4350-4364.	8.2	178
23	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. Clinical Colorectal Cancer, 2018, 17, e513-e518.	2.3	24
24	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma. Annals of Surgery, 2017, 265, 946-953.	4.2	117
25	Different subtypes of epithelioid sarcoma and their clinical implication: longâ€ŧerm multiâ€ɨnstitutional experience with a rare sarcoma. Apmis, 2017, 125, 223-229.	2.0	15
26	Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis. Oncology Reports, 2017, 38, 3011-3018.	2.6	25
27	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget, 2017, 8, 31169-31179.	1.8	13
28	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget, 2017, 8, 113494-113501.	1.8	34
29	Emerging targeted therapies in advanced bladder cancer. Translational Cancer Research, 2017, 6, S666-S676.	1.0	3
30	Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. Journal of Cancer, 2016, 7, 1550-1556.	2.5	16
31	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Oncotarget, 2016, 7, 8055-8066.	1.8	42
32	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer, 2016, 16, 385.	2.6	46
33	Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. Cancer Cell, 2016, 30, 953-967.	16.8	259
34	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer, 2016, 16, 434.	2.6	124
35	Methylation-dependent regulation of HIF-1α stability restricts retinal and tumour angiogenesis. Nature Communications, 2016, 7, 10347.	12.8	159
36	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 3938-3945.	1.5	13

Снал Кім

#	Article	IF	CITATIONS
37	Novel Glycosylated VEGF Decoy Receptor Fusion Protein, VEGF-Grab, Efficiently Suppresses Tumor Angiogenesis and Progression. Molecular Cancer Therapeutics, 2015, 14, 470-479.	4.1	24
38	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma Journal of Clinical Oncology, 2015, 33, 10565-10565.	1.6	6
39	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer Journal of Clinical Oncology, 2015, 33, e15020-e15020.	1.6	0
40	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer Journal of Clinical Oncology, 2015, 33, 4113-4113.	1.6	0
41	Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. Cancer Cell, 2014, 25, 102-117.	16.8	109
42	Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Molecular Cancer, 2011, 10, 36.	19.2	82
43	Clinical Value of Ezrin Expression in Primary Osteosarcoma. Cancer Research and Treatment, 2009, 41, 138.	3.0	39
44	Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. Cancer Research and Treatment, 2009, 41, 196.	3.0	25
45	Clinical Experience of Anesthesia for Open Heart Surgery - 100 cases. Daehan Macwi'gwa Haghoeji, 1990, 23, 630.	0.2	0
46	A Case of Unilateral Blindness Occuring During General Anesthesia for Neurosurgical Operation. Daehan Macwi'gwa Haghoeji, 1989, 22, 770.	0.2	1
47	Retrograde Tracheal Intubation through Cricothyroid Membrane. Daehan Macwi'gwa Haghoeji, 1989, 22, 934.	0.2	0
48	Paraplegia following Epidural Analgesia. Daehan Macwi'gwa Haghoeji, 1988, 21, 389.	0.2	1
49	Invasive and Non-invasive Blood Pressure Measurement during Anesthesia. Daehan Macwi'gwa Haghoeji, 1987, 20, 9.	0.2	0
50	The Incidence and Causes of Failed Spinal Anesthesia. Daehan Macwi'gwa Haghoeji, 1987, 20, 172.	0.2	0
51	Transcutaneous Monitoring of PO2 and PCO2 during General Anesthesia in Adult Patient. Daehan Macwi'gwa Haghoeji, 1985, 18, 244.	0.2	0
52	A Clinieal Study of the Effect of Steroid Administered in Epidural Space for Back Pain and Sciatica. Daehan Macwi'gwa Haghoeji, 1984, 17, 121.	0.2	0